TY - T1的日常生活的活动和生活质量的改善措施Hoehn,Yahr子组先进的帕金森症患者治疗后IPX066,延长释放carbidopa-levodopa (P4.008) JF -神经学乔-神经学六世- 88 - 16补充SP - P4.008盟罗希特迪豪盟提出琳德姆德尔伊丽莎白-拉蒙·吉尔盟盟资格成为-罗伯特·鲁宾斯盟Suneel 首页Gupta Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P4.008.abstract N2 -目的:描述延长释放的影响carbidopa-levodopa (ER CD-LD)日常生活活动(ADL)和子组的生活质量先进的基于Hoehn PD患者,Yahr (H& Y)阶段。背景:ER CD-LD (IPX066 RYTARY®)是一种口服,CD-LD胶囊配方。初始峰值大约一个小时后,等离子体左旋多巴浓度维持大约4 - 5小时。设计/方法:ADVANCE-PD检查的有效性和安全性ER与速释(IR) CD-LD先进的PD患者。病人(n = 393)接受13周的双盲治疗与ER或红外CD-LD。基线的变化统一帕金森病评定量表(UPDRS)第二部分(ADL)分数和39-item帕金森病问卷(PDQ-39)检查治疗每个H& Y阶段(i II和iii iv)小组在这事后分析。结果:在整个研究中,UPDRS ADL(术中;. 01)和PDQ-39总分(术中;. 05)与ER和红外显著提高。ER也产生一个数值更大,但非重大的改进从基线与红外UPDRS H& ADL量表;Y i ii(意思是(SD): ER和−0.5−1.7(3.7)(3.4)对IR)和H& Y iii iv (ER和+ 0.2−0.9(4.1)(4.5)红外)子组。虽然PDQ-39总分提高数值,之间没有统计上的显著差异治疗组H& Y i ii (−2.6 (12.7) ER和对IR) + 0.1(9.7)或H& Y iii iv (ER和−4.4−5.3(11.4)(11.5)红外)子群。 For the H&Y III–IV subgroup, PDQ-39 Mobility scores were significantly better for ER vs. IR (P<.04); this improvement was not statistically significant in the H&Y I–II subgroup.Conclusions: Compared with IR, treatment with ER CD-LD tended to produce greater improvements in the UPDRS ADL and the PDQ-39 scale in both H&Y I–II and H&Y III–IV subgroups.Study Supported by: Impax Laboratories, Inc.Disclosure: Dr. Dhall has received personal Impax, Merz, Teva, Acadia, Medtronic, UCB, and IO Therapeutics as a speaker and/or consultant. Dr. Gil has received personal compensation for activities with Impax Laboratories, Inc., as a participant in their speaker's bureau. Dr. Gil has been an investigator in clinical trials sponsored by Impax Laboratories, Inc. Dr. Lindemulder has received personal compensation for activities with Impax Laboratories Inc. as an employee. Dr. Rubens has received personal compensation for activities with Impax Laboratories, Inc., as an employee. Dr. Gupta has received personal compensation for activities with Impax Laboratories as an employee. ER -